Arbutus Biopharma Reports Director Changes and Compensation
Ticker: ABUS · Form: 8-K · Filed: Oct 11, 2024 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Oct 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
Related Tickers: ABUS
TL;DR
Arbutus Biopharma (ABUS) filed an 8-K detailing board changes and executive comp. Watch for updates.
AI Summary
Arbutus Biopharma Corp. filed an 8-K on October 11, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, indicating ongoing corporate activities and potential shifts in leadership or financial reporting.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts or governance adjustments that may impact future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directorship and executive compensation can indicate internal shifts that may affect company strategy and future performance.
Key Players & Entities
- Arbutus Biopharma Corp. (company) — Registrant
- October 11, 2024 (date) — Date of earliest event reported
- 701 Veterans Circle (location) — Business and mailing address
- Warminster, Pennsylvania (location) — Business and mailing address
- TEKMIRA PHARMACEUTICALS Corp (company) — Former company name
FAQ
What specific changes were made to the board of directors?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" as an item of information, but the specific details of these changes are not provided in the excerpt.
What are the details of the compensatory arrangements for certain officers?
The filing lists "Compensatory Arrangements of Certain Officers" as an item of information, but the specific details of these arrangements are not included in the provided text.
When was Arbutus Biopharma Corporation incorporated?
Arbutus Biopharma Corporation was incorporated in British Columbia, Canada.
What is Arbutus Biopharma's fiscal year end?
Arbutus Biopharma's fiscal year ends on December 31st.
What is the SIC code for Arbutus Biopharma Corp?
The Standard Industrial Classification (SIC) code for Arbutus Biopharma Corp. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 635 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-10-11 16:07:36
Filing Documents
- abus-20241011.htm (8-K) — 31KB
- firstamendmenttomjsemploym.htm (EX-10.1) — 47KB
- 0001447028-24-000084.txt ( ) — 210KB
- abus-20241011.xsd (EX-101.SCH) — 2KB
- abus-20241011_lab.xml (EX-101.LAB) — 21KB
- abus-20241011_pre.xml (EX-101.PRE) — 12KB
- abus-20241011_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 First Amendment to Executive Employment Agreement, dated October 11, 2024, by and between Michael J. Sofia and Arbutus Biopharma, Inc. 104 Cover page interactive data file (formatted as inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 11, 2024 ARBUTUS BIOPHARMA CORPORATION By: /s/ David C. Hastings Name: David C. Hastings Title: Chief Financial Officer